Finance

Lists
Q2 2027 earnings • in 4 days
See details
RDY:NYSE
Dr Reddy's Laboratories Ltd
၁၃.၀၇ US$
+၁.၃၂%
(+၀.၁၇) 1D
အောက် ၁၆, GMT-၄ ၁၆:၀၀:၀၇  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RDY...
Open
၁၃.၀၀ US$
High
၁၃.၀၇ US$
Low
၁၂.၉၄ US$
Mkt. cap
ဋေ ၁.၀၈ ထ
Avg. vol.
၃.၁၉ သန်း
Volume
၂.၀၀
Dividend
၀.၆၄%
Quarterly dividend
၀.၀၂ US$
Ex-dividend date
၂၀၂၆ ဇူ ၁၀
P/E ratio
၃၁.၂၄
52-wk high
၁၅.၆၇ US$
52-wk low
၁၁.၃၆ US$
EPS
၀.၄၂ US$
Beta
၀.၃၀
Shares outstanding
၈၃.၄၆ ကုဋေ
No. of employees
၃ သောင်း
Open
၁၃.၀၀ US$
High
၁၃.၀၇ US$
Low
၁၂.၉၄ US$
Mkt. cap
ဋေ ၁.၀၈ ထ
Avg. vol.
၃.၁၉ သန်း
Volume
၂.၀၀
Dividend
၀.၆၄%
Quarterly dividend
၀.၀၂ US$
Ex-dividend date
၂၀၂၆ ဇူ ၁၀
P/E ratio
၃၁.၂၄
52-wk high
၁၅.၆၇ US$
52-wk low
၁၁.၃၆ US$
EPS
၀.၄၂ US$
Beta
၀.၃၀
Shares outstanding
၈၃.၄၆ ကုဋေ
No. of employees
၃ သောင်း
News stories
From web sources and news partners
ad-hoc-news.de
ad-hoc-news.de
·
ပြီးခဲ့သည့် ၃ နာရီ
Dr Reddy reported three FDA observations before Dr Reddy stock results
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr. Wikipedia
About Dr Reddy's Laboratories Ltd
CEOErez Israeli
Employees၂.၇၅ သောင်း
Founded၁၉၈၄
HeadquartersHyderabad, အန်ဒရာပရာဒစ် ပြည်နယ်, အိန္ဒိယ
Sector-
Analyst ratings
Based on 2 analysts giving stock ratings to RDY in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for RDY in the last 3 months.
Highest
Current ၁၃.၀၇ US$
၁၄.၈၀ US$ (+၁၃.၂၄%)
Average
၁၄.၈၀ US$ (+၁၃.၂၄%)
Lowest
၁၄.၈၀ US$ (+၁၃.၂၄%)
Analyst
Recommendation
Action
Price target
Projected
Date
Tausif Shaikh
Exane BNP Paribas
Buy
Upgraded
၁၄.၈၀ US$
+၁၃.၂%
10/12/2026
Neha Manpuria
Bank of America Securities
Buy
Maintained
-
-
10/01/2026
Unknown Analyst
Citi
Sell
Maintained
-
-
04/23/2026
Next call ၄ ရက်အတွင်း
အောက် ၂၃ သောကြာ, ၁၆:၀၀
Fiscal period
Q2 2027
- / ၈.၉၅ ₹
Revenue / Est. (INR)
- / ဋေ ၈.၅၉ ထ
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
ဋေ ၈.၈၁ ထ
ဋေ ၈.၇၃ ထ
ဋေ ၇.၅၂ ထ
ဋေ ၈.၀၇ ထ
Cost of goods sold
ဋေ ၃.၉၉ ထ
ဋေ ၄.၀၅ ထ
ဋေ ၄.၁၅ ထ
ဋေ ၄.၃၂ ထ
Cost of revenue
ဋေ ၃.၉၉ ထ
ဋေ ၄.၀၅ ထ
ဋေ ၄.၁၅ ထ
ဋေ ၄.၃၂ ထ
Research and development expenses
၆၂၀.၂၀ ဋေ
၆၁၄.၉၀ ဋေ
၅၄၆.၃၀ ဋေ
၅၇၆.၆၀ ဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
ဋေ ၂.၆၄ ထ
ဋေ ၂.၆၉ ထ
ဋေ ၂.၇၈ ထ
ဋေ ၂.၈၈ ထ
Operating expense
ဋေ ၃.၁၉ ထ
ဋေ ၃.၂၅ ထ
ဋေ ၃.၂၅ ထ
ဋေ ၃.၄၁ ထ
Total operating expenses
ဋေ ၇.၁၈ ထ
ဋေ ၇.၂၉ ထ
ဋေ ၇.၄၀ ထ
ဋေ ၇.၇၃ ထ
Operating income
ဋေ ၁.၆၂ ထ
ဋေ ၁.၄၃ ထ
၁၁၅.၉၀ ဋေ
၃၄၃.၁၀ ဋေ
Other non operating income
၁၂၇.၇၀ ဋေ
၅၇.၀၀ ကုဋေ
၅၁.၂၀ ကုဋေ
-
EBT including unusual items
ဋေ ၁.၈၄ ထ
ဋေ ၁.၅၄ ထ
၁၉၉.၁၀ ဋေ
၅၅၂.၆၀ ဋေ
EBT excluding unusual items
ဋေ ၁.၇၈ ထ
ဋေ ၁.၅၅ ထ
၁၈၂.၅၀ ဋေ
၄၀၉.၂၀ ဋေ
Income tax expense
၄၀၈.၁၀ ဋေ
၃၅၃.၃၀ ဋေ
-၂၁.၄၀ ကုဋေ
၁၁၇.၈၀ ဋေ
Effective tax rate
၂၂.၂၄%
၂၂.၉၀%
-၁၀.၇၅%
၂၁.၃၂%
Other operating expenses
-၇၄.၀၀ ကုဋေ
-၅၉.၁၀ ကုဋေ
-၆၉.၃၀ ကုဋေ
-၄၇.၇၀ ကုဋေ
Net income
ဋေ ၁.၄၄ ထ
ဋေ ၁.၂၁ ထ
၂၂၀.၁၀ ဋေ
၄၄၃.၅၀ ဋေ
Net profit margin
၁၆.၃၂%
၁၃.၈၆%
၂.၉၃%
၅.၅၀%
Earnings per share
၁၇.၈၇
၁၄.၇၇
၅.၇၄
၅.၃၃
Interest and investment income
၉၁.၂၀ ကုဋေ
၇၉.၆၀ ကုဋေ
၈၉.၀၀ ကုဋေ
၉၉.၉၀ ကုဋေ
Interest expense
-၉၀.၇၀ ကုဋေ
-၉၄.၄၀ ကုဋေ
-၁၀၅.၇၀ ဋေ
-၁၂၅.၅၀ ဋေ
Net interest expenses
၅.၀၀ သန်း
-၁၄.၈၀ ကုဋေ
-၁၆.၇၀ ကုဋေ
-၂၅.၆၀ ကုဋေ
Depreciation and amortization charges
-
-
-
-
EBITDA
ဋေ ၂.၁၃ ထ
ဋေ ၁.၉၅ ထ
၅၀၃.၃၀ ဋေ
၈၈၀.၃၀ ဋေ
Gain or loss from assets sale
-၃၀.၈၀ ကုဋေ
-၁၇.၉၀ ကုဋေ
-၂၁၀.၀၀ ဋေ
-၃၆.၈၀ ကုဋေ
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google အက်ပ်များ